rs587778862
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_000321.3(RB1):c.217_220delAGAG(p.Arg73LeufsTer3) variant causes a frameshift change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000321.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RB1 | NM_000321.3 | c.217_220delAGAG | p.Arg73LeufsTer3 | frameshift_variant | Exon 2 of 27 | ENST00000267163.6 | NP_000312.2 | |
RB1 | NM_001407165.1 | c.217_220delAGAG | p.Arg73LeufsTer3 | frameshift_variant | Exon 2 of 27 | NP_001394094.1 | ||
RB1 | NM_001407166.1 | c.217_220delAGAG | p.Arg73LeufsTer3 | frameshift_variant | Exon 2 of 17 | NP_001394095.1 | ||
RB1 | NM_001407167.1 | c.217_220delAGAG | p.Arg73LeufsTer3 | frameshift_variant | Exon 2 of 3 | NP_001394096.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Retinoblastoma Pathogenic:1
This sequence change creates a premature translational stop signal (p.Arg73Leufs*3) in the RB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RB1 are known to be pathogenic (PMID: 17096365). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with retinoblastoma (PMID: 11317357). This variant is also known as g.5503_5506del4 (E73fsX75). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.